Phathom Pharmaceuticals, Inc. (PHAT) stock
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.50−0.38 (-6.46%)
Close on Nov 17, 2026Market cap $447.10MP/E –Yield –
Phathom Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Phathom Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$25.46M. For fiscal 2025 it was -$159.99M. The highest annual figure on record is -$1.23M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$159.99M | – |
| FY2024 | Dec 31, 2024 | -$277.47M | – |
| FY2023 | Dec 31, 2023 | -$167.31M | – |
| FY2022 | Dec 31, 2022 | -$172.44M | – |
| FY2021 | Dec 31, 2021 | -$135.08M | – |
| FY2020 | Dec 31, 2020 | -$125.67M | – |
| FY2019 | Dec 31, 2019 | -$106.22M | – |
| FY2018 | Dec 31, 2018 | -$1.23M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$85.00K | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.48M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$59.92M | – |
| Q1 FY2025 | Mar 31, 2025 | -$78.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$59.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$70.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$77.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$69.95M | – |
| Q4 FY2023 | Dec 31, 2023 | -$69.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.08M | – |
| Q4 FY2022 | Dec 31, 2022 | -$46.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$45.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$37.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$33.14M | – |
| Q2 FY2021 | Jun 30, 2021 | -$35.32M | – |
| Q1 FY2021 | Mar 31, 2021 | -$33.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$52.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$32.83M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.02M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.38M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.69M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$83.01M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$451.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$268.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$255.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$251.00K | – |
See a number that looks wrong?